Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
To evaluate the safety and tolerability of MSC_apceth_101.
Advanced Gastrointestinal Cancer
DRUG: MSC_apceth_101
Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute, day 56 (+/- 7) in patient group 1 and day 29 (+/-3) in patient group 2
To evaluate the safety and tolerability of MSC_apceth_101.